Proteomics International is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.
Established in 2001, Proteomics International is recognised as a global leader in the field of proteomics. It operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
Data analysis conducted at Proteomics International is performed to ISO 17025 laboratory standard. ISO 17025 is the most widely used laboratory standard for US Federal testing laboratories, including the FDA’s own testing facilities and is recognised worldwide as the main ISO standard used by testing and calibration laboratories.
Proteomics International has been providing analytical services since 2001 and became the world’s first facility to receive ISO 17025 accreditation for proteomics services in 2009.
Accreditation ISO 17025 demonstrates technical competence and Proteomics International operates in accordance with the OECD Principles of Good Laboratory Practice (GLP).
Analytical services – specialist contract research, analytical testing and consultancy
Diagnostics – biomarkers of disease and personalised medicine
Therapeutics – peptide drug discovery from venoms
Proteomics is the large-scale mapping of the structure and function of proteins.